Open Save New
FeedNavigator / National Library of Health Sciences
 
  
Tutkijat / Oulu
AddAla-Kokko, L.
AddAla-Kokko, T(ero)
AddAla-Korpela, M(ika)
AddAlahuhta, S.
AddAlen, M.
AddAntikainen, R.
AddAnttonen, V(uokko)
AddBiancari, F.
AddBloigu, R(isto)
AddEskelinen, S.
AddFlinkkilä, T(apio)
AddHakkola, J.
AddHallman, M.
AddHartikainen, A(nna)-L(iisa)
AddHausen, H.
AddHautala, N(ina)
AddHautala, T(imo)
AddHeape, A.
AddHerzig, K(arl)-H(einz)
AddHillbom, M.
AddHiltunen, J.K.
AddHörkko, S.
AddHuikuri, H
AddHukkanen J(anne)
AddIgnatius, J.
AddIsohanni, M.
AddJaakkola, J.
AddJaakkola, M(aritta) S.
AddJaakola, V-P.
AddJämsä, T(imo)
AddJanhonen, S.
AddJärvelin, M(arjo)-R(iitta)
AddJokelainen, J(ari)
AddJuffer, A.H.
AddJunttila, J(uhani)
AddJuvonen, T.
AddKaarteenaho, R(iitta)
AddKajantie, E(ero)*(THL/OY)
AddKarppinen (Koivunen), P(eppi)
AddKarppinen, J(aro)
AddKarttunen, T.J.
AddKeinänen-Kiukaanniemi, S(irkka)
AddKerkelä, R(isto)
AddKesäniemi, Y.A.
AddKettunen, J(ohannes)
AddKietzmann, T(homas).
AddKivirikko, K.I.
AddKnuuttila, M.
AddKoivukangas, J.
AddKursula, P.
AddKyngäs, H.
AddLarivaara, P.
AddLarmas, M.
AddLehenkari, P(etri)
AddLehtiö, L(ari)
AddLeppilahti, J.
AddLuukinen, H.
AddMainio A
AddMajamaa, K.
AddMäki, P(irjo)
AddMäkikallio, T.
AddMännikkö, M(inna)
AddManninen, A(ki).
AddMartikainen, H(annu)
AddMiettunen, J(ouko)
AddMyllyharju, J.
AddMyllylä, R.
AddMyllylä, V.
AddNäyhä, S.
AddNeubauer, P.
AddNieminen, M(iika) T.
AddNieminen, P(entti)
AddNiinimäki, J(aakko)
AddOhukainen, P(auli)
AddOikarinen, A.
AddOikarinen, K.
AddPelkonen, O(lavi)
AddPetäjä-Repo, U.E.
AddPihlajaniemi, T.
AddPirttiniemi, P(ertti)
AddPuistola, U(lla)
AddRajaniemi, H.J.
AddRämet, M(ika)
AddRäsänen, P.
AddRaustia, A.
AddRemes, A(nne)
AddRisteli, J.
AddRistiniemi, J.
AddRuddock, L.W.
AddRuokonen, A.
AddRuskoaho, H.
AddRyynänen, M.
AddSaarakkala, S.
AddSaari, A.
AddSalo, T(uula)
AddSándor, G(eorge) K.
AddSavolainen, E-R.
AddSavolainen, M.J.
AddSavolainen, O.
AddSillanpää, M(ikko).
AddSoininen, R.
AddSorri, M.
AddTaanila, A.
AddTapiainen, T(erhi)
AddTervonen, O(smo)
AddTimonen, M(arkku)
AddTjäderhane, L.
AddTurpeenniemi-Hujanen, T.
AddTuukkanen, J(uha)
AddTuulonen, A.
AddUhari, M.
AddUkkola, O(lavi)
AddUusimaa, J.
AddVainio, O.
AddVainio, S.
AddVeijola, J(uha)
AddVeijola, R(iitta)
AddVirokannas, H.
AddVoipio, H(anna)-M(arja)
AddVuolteenaho, O.
AddWeckström, M.
AddWei, GH.
AddWierenga, R.K.
AddWinqvist, R.
AddYlänne, J.
AddYlitalo, K(ari)

Scholar Chart >>



»My Articles

»Latest Feeds

»Popular Feeds
Search Feed Catalog by Name:

Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)12 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)22 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)51 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)55 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)58 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)58 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)58 dayssaveRefWorks
Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study.Pelkonen, O(lavi)394 dayssaveRefWorks
Integration of epidemiological findings with mechanistic evidence in regulatory pesticide risk assessment: EFSA experiences.Pelkonen, O(lavi)422 dayssaveRefWorks
Editorial.Pelkonen, O(lavi)532 dayssaveRefWorks
Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance.Pelkonen, O(lavi)688 dayssaveRefWorks
Obfuscating Transparency?Pelkonen, O(lavi)714 dayssaveRefWorks
Toxicology meets Pharmacodynamics and Pharmacokinetics - New Concepts, Models and In Vitro Approaches and Tools.Pelkonen, O(lavi)735 dayssaveRefWorks
CYP Induction and Xeno-Sensing Receptors PXR, CAR, AHR and PPARα at the Crossroads of Toxicokinetics and Toxicodynamics.Pelkonen, O(lavi)842 dayssaveRefWorks
Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research.Pelkonen, O(lavi)1132 dayssaveRefWorks
Cardiac safety of ophthalmic timolol.Pelkonen, O(lavi)1349 dayssaveRefWorks
Upholding science in health, safety and environmental risk assessments and regulations.Pelkonen, O(lavi)1382 dayssaveRefWorks
Cardiac safety of ophthalmic timolol.Pelkonen, O(lavi)1412 dayssaveRefWorks
Response to“The Path Forward on Endocrine Disruptors Requires Focus”.Pelkonen, O(lavi)1499 dayssaveRefWorks
Tandem mass spectrometric analysis of S- and N-linked glutathione conjugates of pulegone and menthofuran and identification of P450 enzymes mediating their formation.Pelkonen, O(lavi)1572 dayssaveRefWorks
Metabolism and metabolite profiles in vitro and in vivo of ospemifene in humans and preclinical species.Pelkonen, O(lavi)1687 dayssaveRefWorks
Differentiation-Promoting Medium Additives for Hepatocyte Cultivation and Cryopreservation.Pelkonen, O(lavi)1783 dayssaveRefWorks
Formation of GSH-trapped reactive metabolites in human liver microsomes, S9 fraction, HepaRG-cells, and human hepatocytes.Pelkonen, O(lavi)1786 dayssaveRefWorks
Drug Metabolism - From In Vitro to In Vivo, from Simple to Complex Reflections of the BCPT Nordic Prize 2014 Awardee.Pelkonen, O(lavi)1843 dayssaveRefWorks
Principles of Pharmacology and Toxicology Also Govern Effects of Chemicals on the Endocrine System.Pelkonen, O(lavi)1857 dayssaveRefWorks
Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer.Pelkonen, O(lavi)1946 dayssaveRefWorks
Biotransformation in vitro: An essential consideration in the quantitative invitro-to-in vivo extrapolation (QIVIVE) of toxicity data.Pelkonen, O(lavi)2038 dayssaveRefWorks
Reactive Metabolites in Early Drug Development: Predictive in Vitro Tools.Pelkonen, O(lavi)2087 dayssaveRefWorks
Why is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality?Pelkonen, O(lavi)2224 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2363 dayssaveRefWorks
Human variation and CYP enzyme contribution in benfuracarb metabolism in human in vitro hepatic models.Pelkonen, O(lavi)2486 dayssaveRefWorks
Analytical challenges for conducting rapid metabolism characterization for QIVIVE.Pelkonen, O(lavi)2494 dayssaveRefWorks
Open letter to the European commission: scientifically unfounded precaution drives European commission's recommendations on EDC regulation, while defying common sense, well-established science, and risk assessment principles.Pelkonen, O(lavi)2500 dayssaveRefWorks
Comparative metabolism of benfuracarb in in vitro mammalian hepatic microsomes model and its implications for chemical risk assessment.Pelkonen, O(lavi)2507 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2521 dayssaveRefWorks
Estimation of health risk by using toxicokinetic modelling: A case study of polychlorinated biphenyl PCB153.Pelkonen, O(lavi)2522 dayssaveRefWorks
Effects of ospemifene on drug metabolism mediated by cytochrome p450 enzymes in humans in vitro and in vivo.Pelkonen, O(lavi)2533 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2539 dayssaveRefWorks
Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.Pelkonen, O(lavi)2542 dayssaveRefWorks
"Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.''Pelkonen, O(lavi)2542 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2549 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2550 dayssaveRefWorks
Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations.Pelkonen, O(lavi)2584 dayssaveRefWorks
Thujone and thujone-containing herbal medicinal and botanical products: toxicological assessment.Pelkonen, O(lavi)2766 dayssaveRefWorks
The inhibition of major human hepatic cytochrome P450 enzymes by 18 pesticides: comparison of the N-in-one and single substrate approaches.Pelkonen, O(lavi)2956 dayssaveRefWorks
Review of current and "omics" methods for assessing the toxicity (genotoxicity, teratogenicity and nephrotoxicity) of herbal medicines and mushrooms.Pelkonen, O(lavi)3033 dayssaveRefWorks
Omics and its potential impact on R&D and regulation of complex herbal products.Pelkonen, O(lavi)3063 dayssaveRefWorks
Characterization of human cytochrome P450 induction by pesticides.Pelkonen, O(lavi)3063 dayssaveRefWorks
A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing - t4 report*.Pelkonen, O(lavi)3067 dayssaveRefWorks
Significant interspecies differences in induction profiles of hepatic CYP enzymes by TCDD in bank and field voles.Pelkonen, O(lavi)3095 dayssaveRefWorks
 XML / RSS feed
report
next »